Neurosense Therapeutics Ltd (NRSN) Stock Price, Quote & News

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 9 799 6183

Website: www.neurosense-tx.com

Address:

Building B, 11 HaMenofim Street, Herzliya, Israel

stevelue Aug. 21 at 3:49 PM

$NRSN the XBI (Biotech Index) is at High of the Day...Let's roll

0 · Reply

Zofar Aug. 21 at 3:00 PM

$NRSN company interest is basically dead! vol standing on 40k is ridicules! Alon the idiot needs to do something quick!

0 · Reply

Zofar Aug. 21 at 1:29 PM

$NRSN was an ok week, hope next week will bring important announcements with it…

0 · Reply

stevelue Aug. 20 at 7:53 PM

$NRSN the XBI biotech index at High of Day..Let's roll!

1 · Reply

Frankquehe1 Aug. 20 at 6:37 PM

$NRSN That was me that just bought...30,000 shares My dad died from ALS. I know I shouldnt invest emotionally but something shifted me over here.

3 · Reply

Induraman Aug. 20 at 6:16 PM

$NRSN So do we know what was still needed for Canadian approval? Never really got that answer?

1 · Reply

Stekli27 Aug. 20 at 5:06 PM

$NRSN this is good, we can get the missing additional data 🙃

1 · Reply

stevelue Aug. 20 at 4:53 PM

$NRSN overall mkt recovering here...the XBI (Biotech index is Green)

0 · Reply

Induraman Aug. 20 at 4:17 PM

$NRSN So what does 6 k tell us?

1 · Reply

stevelue Aug. 20 at 3:54 PM

D. Boral Capital has Adjusted their stance on NeuroSense Therapeutics ( $NRSN ), setting the rating to BUY, with a Target price of 14.00.....Cheers!

0 · Reply

NeuroSense Provides Business Update and Progress for the First Half of 2025

Jul 22, 2025, 8:42 AM EDT - 4 weeks ago

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

May 12, 2025, 3:08 PM EDT - 3 months ago

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 7, 2025, 8:45 AM EDT - 3 months ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

Apr 24, 2025, 9:09 AM EDT - 4 months ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

Apr 9, 2025, 8:30 AM EDT - 4 months ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Apr 7, 2025, 5:14 PM EDT - 4 months ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Apr 4, 2025, 9:10 AM EDT - 4 months ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Mar 17, 2025, 8:30 AM EDT - 5 months ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Jan 6, 2025, 9:00 AM EST - 8 months ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Dec 23, 2024, 9:00 AM EST - 8 months ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Dec 18, 2024, 10:25 AM EST - 8 months ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

Dec 11, 2024, 9:25 AM EST - 9 months ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Dec 4, 2024, 8:30 AM EST - 9 months ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Dec 2, 2024, 8:30 AM EST - 9 months ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Nov 21, 2024, 9:20 AM EST - 9 months ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Oct 28, 2024, 8:30 AM EDT - 10 months ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Oct 24, 2024, 8:30 AM EDT - 10 months ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Oct 15, 2024, 9:15 AM EDT - 11 months ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 9, 2024, 9:00 AM EDT - 11 months ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

Oct 7, 2024, 9:00 AM EDT - 11 months ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Sep 24, 2024, 9:05 AM EDT - 11 months ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

Sep 24, 2024, 9:00 AM EDT - 11 months ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Aug 30, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Aug 7, 2024, 2:00 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

Aug 1, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

Jul 9, 2024, 9:27 AM EDT - 1 year ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Jul 2, 2024, 12:34 PM EDT - 1 year ago

This cheap biotech offers investors a play on ALS if trial data continues to impress

Jul 1, 2024, 8:00 AM EDT - 1 year ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Jun 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Jun 21, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

May 20, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

May 14, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning

May 7, 2024, 8:45 AM EDT - 1 year ago

NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients

May 2, 2024, 9:19 AM EDT - 1 year ago

NeuroSense Announces First Quarter 2024 Business Update

Apr 22, 2024, 8:30 AM EDT - 1 year ago

NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Apr 18, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting

Apr 12, 2024, 8:30 AM EDT - 1 year ago

NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024

Apr 10, 2024, 7:16 PM EDT - 1 year ago

NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement

Apr 9, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

Apr 5, 2024, 9:29 AM EDT - 1 year ago

NeuroSense Announces Year End 2023 Financial Results and Provides Business Update

Feb 21, 2024, 8:30 AM EST - 1 year ago

NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial

Jan 30, 2024, 8:30 AM EST - 1 year ago

NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024

BIIB

Jan 9, 2024, 8:45 AM EST - 1 year ago

NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts

Dec 27, 2023, 5:00 PM EST - 1 year ago

NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Dec 14, 2023, 9:24 AM EST - 1 year ago

NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial

Dec 5, 2023, 8:00 AM EST - 1 year ago

NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints

Dec 4, 2023, 4:01 PM EST - 1 year ago

NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023

Nov 28, 2023, 8:45 AM EST - 1 year ago

NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update

stevelue Aug. 21 at 3:49 PM

$NRSN the XBI (Biotech Index) is at High of the Day...Let's roll

0 · Reply

Zofar Aug. 21 at 3:00 PM

$NRSN company interest is basically dead! vol standing on 40k is ridicules! Alon the idiot needs to do something quick!

0 · Reply

Zofar Aug. 21 at 1:29 PM

$NRSN was an ok week, hope next week will bring important announcements with it…

0 · Reply

stevelue Aug. 20 at 7:53 PM

$NRSN the XBI biotech index at High of Day..Let's roll!

1 · Reply

Frankquehe1 Aug. 20 at 6:37 PM

$NRSN That was me that just bought...30,000 shares My dad died from ALS. I know I shouldnt invest emotionally but something shifted me over here.

3 · Reply

Induraman Aug. 20 at 6:16 PM

$NRSN So do we know what was still needed for Canadian approval? Never really got that answer?

1 · Reply

Stekli27 Aug. 20 at 5:06 PM

$NRSN this is good, we can get the missing additional data 🙃

1 · Reply

stevelue Aug. 20 at 4:53 PM

$NRSN overall mkt recovering here...the XBI (Biotech index is Green)

0 · Reply

Induraman Aug. 20 at 4:17 PM

$NRSN So what does 6 k tell us?

1 · Reply

stevelue Aug. 20 at 3:54 PM

D. Boral Capital has Adjusted their stance on NeuroSense Therapeutics ( $NRSN ), setting the rating to BUY, with a Target price of 14.00.....Cheers!

0 · Reply

black_ambition Aug. 20 at 3:05 PM

$NRSN https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=319392555&type=HTML&cdn=b38a3481fa906d6076691460d98f3b4d&formType=6-K&dateFiled=2025-08-20&cik=1875091&symbol=1875091&companyName= I think this is really impressive. I believe people with ALS typically live only about 4 years after the onset of symptoms. Prime C patients have been taking the therapy for more than 5 years, and living for more than 7.

3 · Reply

Zofar Aug. 20 at 2:13 PM

$NRSN so now we have started with stupid meaningless k-6 fillings? what is this shit head doing?

1 · Reply

mmtiddy Aug. 20 at 1:55 PM

$NRSN Bro, why is this worth reporting as a 6-K? 20% of 15 patients is just like 3?

1 · Reply

DonCorleone77 Aug. 20 at 1:51 PM

$NRSN NeuroSense reports 20% of people with ALS from Phase 2a study remain on PrimeC

2 · Reply

rml360 Aug. 20 at 1:38 PM

$NRSN all of a sudden someone woke up and thought this is undervalued lol

1 · Reply

Zofar Aug. 20 at 1:33 PM

$NRSN another day another bust… we have return to that…

0 · Reply

stevelue Aug. 19 at 6:42 PM

$NRSN Added the dip, and still added....Cheers

0 · Reply

forza_juve Aug. 19 at 4:00 PM

$NRSN Down on very low volume. It’s all tied to the shitty market day we are having today. On average I would say 8-9 tickers out of 10 are red on my watchlist which consists of around 50 stocks. So…I’m not worried. If it traded 3mil shares and down 6-10% I would be more worried but not at the current volume of 36k shares

0 · Reply

funnymoney90210 Aug. 19 at 3:18 PM

$NRSN Alon blew the deal with his greed..Now he's out of time and money

1 · Reply

induraman64 Aug. 19 at 1:55 PM

$NRSN I kinda like the silent, hopeful it means something is brewing.

0 · Reply

Zofar Aug. 19 at 1:08 PM

$NRSN one thing i wonder about is why Alon so stuck on the deal with current company? is it that good that he is willing to wait so much and to go through so much for it? he said that they had a few options and proposals and that they chose the one they believed the most in.., the can choose to go with other company….really weird…

1 · Reply

Zofar Aug. 18 at 9:27 PM

$NRSN to say the truth, at least Alon is dead silent now. i hope he is working on something great, it is his last chance to redeem himself and his reputation…

0 · Reply

Market Cap	15.85M
Revenue (ttm)	0.00
Net Income (ttm)	-10.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	263,897
Avg Vol	393,816
Day's Range	N/A - N/A
Shares Out	13.67M
Stochastic %K	49%
Beta	1.64
Analysts	Sell
Price Target	$10.75